| pubmed-article:1878020 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C0026447 | lld:lifeskim |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C0021888 | lld:lifeskim |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C0430943 | lld:lifeskim |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C0012471 | lld:lifeskim |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1878020 | lifeskim:mentions | umls-concept:C0489618 | lld:lifeskim |
| pubmed-article:1878020 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1878020 | pubmed:dateCreated | 1991-4-12 | lld:pubmed |
| pubmed-article:1878020 | pubmed:abstractText | Topical application of Prostaglandin F2 alpha (PGF2 alpha) to the eye reduces intraocular pressure (IOP) in all mammalian species studied thus far, including humans. The L-isopropylester derivative is currently the one most commonly used in experimental and clinical studies. Dose-response relationships were determined between PGF2 alpha-IE and IOP, pupillary diameter, and refraction in ketamine-anesthetized ocular normotensive cynomolgus monkeys. Single doses of 10 and 30 micrograms had smaller and less consistent but longer lasting IOP-lowering effects than repeated doses (twice daily for 3 days) of 1-5 micrograms. For repeated dosing in this manner, the just-maximal dose is probably between 2-5 micrograms, producing a approximately 70% reduction in IOP to a final IOP of approximately 5 mm Hg. Continuing treatment for up to 18 days did not further enhance the efficacy of twice daily treatment with a submaximal 1-microgram dose. Partial reversal of anesthesia-induced tonic accommodation occurred with single 10- and 30-micrograms doses and with repeated 1-microgram doses, but additional myopia of 0.5-1.5 diopters was induced with repeated higher doses. These physiologic findings and previous morphologic data are consistent with a proposed dual PG action on the ciliary muscle, one involving a short-onset long-lasting direct effect on the muscle fibers (causing relaxation and narrowing of the muscle bundles) and the second involving a slowly developing but shorter duration dissolution of the intermuscular connective tissues. | lld:pubmed |
| pubmed-article:1878020 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1878020 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1878020 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1878020 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1878020 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1878020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1878020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1878020 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1878020 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:1878020 | pubmed:issn | 0146-0404 | lld:pubmed |
| pubmed-article:1878020 | pubmed:author | pubmed-author:KaufmanP LPL | lld:pubmed |
| pubmed-article:1878020 | pubmed:author | pubmed-author:CrawfordK SKS | lld:pubmed |
| pubmed-article:1878020 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1878020 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:1878020 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1878020 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1878020 | pubmed:pagination | 510-9 | lld:pubmed |
| pubmed-article:1878020 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:meshHeading | pubmed-meshheading:1878020-... | lld:pubmed |
| pubmed-article:1878020 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1878020 | pubmed:articleTitle | Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys. | lld:pubmed |
| pubmed-article:1878020 | pubmed:affiliation | Department of Ophthalmology, University of Wisconsin, Madison. | lld:pubmed |
| pubmed-article:1878020 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1878020 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1878020 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1878020 | lld:pubmed |
